JFG
CLDX icon

Jefferies Financial Group’s Celldex Therapeutics CLDX Stock Holding History

Jefferies Financial Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-27,300
Closed -$982K – 1721
2023
Q1 		$982K Sell
27,300
-75,400
-73% -$3.25M 0.01% 899
2022
Q4 		$4.58M Buy
+102,700
New +$3.67M 0.03% 432

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Jefferies Financial Group's CLDX Position: Q4 2025 in Review

Jefferies Financial Group sold out of Celldex Therapeutics (CLDX) in Q4 2025, closing a stake of 50,000 shares — an estimated $1.29M sold.

Jefferies Financial Group first reported a position in CLDX in Q4 2022 and held it in 7 quarters. The position peaked at $60.4M in Q4 2024. 185 funds tracked by Wall St. Rank hold CLDX as of Q4 2025.

  • Jefferies Financial Group reported no remaining Celldex Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jefferies Financial Group sold 50,000 Celldex Therapeutics shares in Q4 2025, an estimated $1.29M.
  • Jefferies Financial Group first reported a position in Celldex Therapeutics in Q4 2022 and held it in 7 quarters.
  • Jefferies Financial Group's Celldex Therapeutics position peaked at $60.4M in Q4 2024.
  • 185 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2025.

Based on Jefferies Financial Group's 13F filing for Q4 2025, filed 9 Feb 2026.